In a head-to-head phase 3 trial presented at the 2024 World Conference on Lung Cancer (WCLC) – called HARMONi-2 – PD-1xVEGF bispecific ivonescimab cut the risk of disease progression or death ...

At the World Conference on Lung Cancer (WCLC) in San Diego, interim results from the dose optimisation part of the Ideate-Lung01 trial showed the benefit of the 12 mg/kg dose of the antibody-drug ...